Contents

Current Pharmaceutical Design, Volume 12 - Number 33

Editorial [Hot Topic: Alzheimer Drug Design Based on the Amyloid Hypothesis (Executive Editors: D. Munoz-Torrero and P. Camps)]

, 12(33): 4281 - 4282

Diego Munoz-Torrero and Pelayo Camps


DOI: 10.2174/138161206778792958




Vaccine Development for Alzheimers Disease

, 12(33): 4283 - 4293

Kevin A. DaSilva, Isabelle Aubert and JoAnne McLaurin


DOI: 10.2174/138161206778793001




Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimers Disease: Progress and Problems

, 12(33): 4295 - 4312

Jeffrey-Tri Nguyen, Abdellah Yamani and Yoshiaki Kiso


DOI: 10.2174/138161206778792976




Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

, 12(33): 4313 - 4335

Chewki Ziani-Cherif, Bachir Mostefa-Kara and Fatima Z. Brixi-Gormat


DOI: 10.2174/138161206778792994




Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond

, 12(33): 4337 - 4355

Stefanie Leuchtenberger, Dirk Beher and Sascha Weggen


DOI: 10.2174/138161206778793029




The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ

, 12(33): 4357 - 4375

Kenjiro Ono, Hironobu Naiki and Masahito Yamada


DOI: 10.2174/138161206778793010




Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors

, 12(33): 4377 - 4387

Ana Castro and Ana Martinez


DOI: 10.2174/138161206778792985




Molecular and Biochemical Features in Alzheimers Disease

, 12(33): 4389 - 4408

Merce Pallas and Antoni Camins


DOI: 10.2174/138161206778792967




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science